Table 2.
Baseline clinical characteristics in the cardiovascular group and the noncardiovascular group in men.
| Total (n=1194) | Non-CVD group (n=1089) | CVD group (n=105) | t value | p value | |
|---|---|---|---|---|---|
| Age (years) | 67.22 ± 12.11 | 66.75 ± 12.27 | 72.02 ± 8.95 | −5.55 | <0.001 |
| BMI (kg/m2) | 25.30 ± 3.51 | 25.25 ± 3.47 | 25.81 ± 3.88 | −1.57 | 0.118 |
| Diabetic duration (years) | 10.1 (6.1, 15.3) | 10.0 (6.0, 15.2) | 12.8 (7.1, 16.8) | 2.54∗ (Z) | 0.011 |
| Smoking (n, %) | 386 (32.33) | 358 (32.87) | 28 (26.67) | 1.69# (x2) | 0.194 |
| WC (cm) | 91.10 ± 8.81 | 90.90 ± 8.78 | 93.20 ± 8.90 | −2.56 | 0.010 |
| NC (cm) | 38.20 ± 3.80 | 38.22 ± 3.73 | 38.02 ± 4.49 | 0.43 | 0.665 |
| SBP (mmHg) | 129.53 ± 14.50 | 129.26 ± 14.37 | 132.36 ± 15.59 | −2.08 | 0.037 |
| DBP (mmHg) | 78.54 ± 9.06 | 78.54 ± 9.03 | 78.52 ± 9.35 | 0.02 | 0.984 |
| FPG (mmol/L) | 7.90 ± 2.69 | 7.89 ± 2.73 | 7.99 ± 2.27 | −0.41 | 0.681 |
| HbA1c (%) | 7.39 ± 1.67 | 7.38 ± 1.69 | 7.57 ± 1.46 | −1.10 | 0.270 |
| TG (mmol/L) | 1.80 ± 1.48 | 1.80 ± 1.51 | 1.74 ± 1.23 | 0.50 | 0.621 |
| TC (mmol/L) | 5.03 ± 1.20 | 5.02 ± 1.20 | 5.13 ± 1.18 | −0.93 | 0.352 |
| HDL (mmol/L) | 1.24 ± 0.41 | 1.24 ± 0.42 | 1.19 ± 0.35 | 1.53 | 0.128 |
| LDL (mmol/L) | 2.94 ± 0.88 | 2.93 ± 0.89 | 3.00 ± 0.75 | −0.82 | 0.416 |
| Antihypertension medication (n, %) | 669 (56.03) | 597 (54.82) | 72 (68.57) | 7.35# (x2) | 0.007 |
| Antiglycemic medication (n, %) | 1073 (89.87) | 971 (89.16) | 102 (97.14) | 6.69# (x2) | 0.010 |
| Statin (n, %) | 730 (61.14) | 661 (60.7) | 69 (65.71) | 1.01# (x2) | 0.314 |
∗Rank sum test was used, expressed as median (range). #Chi-square was used. CVD, cardiovascular disease; BMI, body mass index; WC, waist circumference; NC, neck circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; TG, triglyceride; TC, total cholesterol; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol.